Abstract
We conducted a double-blind, placebo-controlled, randomized study of 3-month treatment with lymecycline, a form of tetracycline, in reactive arthritis (ReA). Lymecycline therapy significantly decreased the duration of the illness in patients with Chlamydia trachomatis-triggered ReA, but not in other ReA patients. In 2 ReA patients, C trachomatis was found in the throat, an uncommon locale for this organism. Our results suggest that it is important to verify the triggering microbe and that it is beneficial to treat Chlamydia arthritis patients with a prolonged course of tetracycline.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Bacterial / analysis
-
Arthritis, Infectious / drug therapy*
-
Chlamydia Infections*
-
Chlamydia trachomatis / immunology
-
Chlamydia trachomatis / isolation & purification
-
Double-Blind Method
-
Feces / microbiology
-
Humans
-
Lymecycline / adverse effects
-
Lymecycline / therapeutic use*
-
Male
-
Prohibitins
-
Sulfasalazine / therapeutic use
-
Time Factors
-
Yersinia / isolation & purification
Substances
-
Antibodies, Bacterial
-
PHB2 protein, human
-
Prohibitins
-
Sulfasalazine
-
Lymecycline